Protein profiles distinguish stable and progressive chronic lymphocytic leukemia

• Published in: Leukemia & lymphoma Vol. 57; no. 5; pp. 1033 - 1043
• Main Authors: Huang, Pauline Y., Mactier, Swetlana, Armacki, Natalie, Giles Best, O., Belov, Larissa, Kaufman, Kimberley L., Pascovici, Dana, Mulligan, Stephen P., Christopherson, Richard I.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 03.05.2016
• Subjects: Biomarkers, Tumor; Chromatography, Liquid; Chronic lymphocytic leukemia; Cluster Analysis; Disease Progression; Humans; Immunophenotyping; iTRAQ; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; mass spectrometry; Neoplasm Staging; Phenotype; Prognosis; prognostic markers; Proteome; proteomics; Proteomics - methods; selected reaction monitoring; Tandem Mass Spectrometry; iTRAQ; mass spectrometry; Chronic lymphocytic leukemia; prognostic markers; proteomics; selected reaction monitoring
• ISSN: 1042-8194; 1029-2403
• DOI: 10.3109/10428194.2015.1094692

Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in >5 years, but may develop progressive disease with lymphocytes doubling in <12 months. To identify a protein signature for progressive CLL, whole cell extracts of peripheral blood mononuclear cells from patients with CLL (n = 27) were screened using iTRAQ (isobaric tags for relative and absolute quantification) analysis. A total of 84 differentially abundant proteins were identified from patients with stable and progressive CLL. Subsequently, 32 of these proteins were quantified by SRM (selected reaction monitoring) using extracts of purified CD19 + CLL cells from patients (n = 50). Hierarchical clustering of these protein profiles showed two clusters of patients that correlated with progressive and stable CLL, providing signatures that should be useful for triaging patients. Some of the proteins in the progressive cluster have not been linked with CLL, for example, glutamate dehydrogenase 1 and transcription intermediary factor 1-beta.